Cargando…

Review of checkpoint immunotherapy for the management of non-small cell lung cancer

Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Raju, Shine, Joseph, Ranjit, Sehgal, Sameep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074780/
https://www.ncbi.nlm.nih.gov/pubmed/30105218
http://dx.doi.org/10.2147/ITT.S125070
_version_ 1783344486301040640
author Raju, Shine
Joseph, Ranjit
Sehgal, Sameep
author_facet Raju, Shine
Joseph, Ranjit
Sehgal, Sameep
author_sort Raju, Shine
collection PubMed
description Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunotherapy for advanced non-small cell lung cancer (NSCLC) has resulted in a new paradigm of treatment options resulting in improved survival and response rates and has a less severe yet unique toxicity profile when compared to chemotherapy. PD-1 inhibitors, nivolumab and pembrolizumab, and PD-L1 inhibitor, atezolizumab, are currently approved by regulatory authorities for the treatment of advanced NSCLC. This article provides a detailed review of these newer agents, their mechanism of action, side-effect profile, therapeutic indications and current evidence supporting their use in the management of NSCLC.
format Online
Article
Text
id pubmed-6074780
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60747802018-08-13 Review of checkpoint immunotherapy for the management of non-small cell lung cancer Raju, Shine Joseph, Ranjit Sehgal, Sameep Immunotargets Ther Review Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunotherapy for advanced non-small cell lung cancer (NSCLC) has resulted in a new paradigm of treatment options resulting in improved survival and response rates and has a less severe yet unique toxicity profile when compared to chemotherapy. PD-1 inhibitors, nivolumab and pembrolizumab, and PD-L1 inhibitor, atezolizumab, are currently approved by regulatory authorities for the treatment of advanced NSCLC. This article provides a detailed review of these newer agents, their mechanism of action, side-effect profile, therapeutic indications and current evidence supporting their use in the management of NSCLC. Dove Medical Press 2018-07-31 /pmc/articles/PMC6074780/ /pubmed/30105218 http://dx.doi.org/10.2147/ITT.S125070 Text en © 2018 Raju et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Raju, Shine
Joseph, Ranjit
Sehgal, Sameep
Review of checkpoint immunotherapy for the management of non-small cell lung cancer
title Review of checkpoint immunotherapy for the management of non-small cell lung cancer
title_full Review of checkpoint immunotherapy for the management of non-small cell lung cancer
title_fullStr Review of checkpoint immunotherapy for the management of non-small cell lung cancer
title_full_unstemmed Review of checkpoint immunotherapy for the management of non-small cell lung cancer
title_short Review of checkpoint immunotherapy for the management of non-small cell lung cancer
title_sort review of checkpoint immunotherapy for the management of non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074780/
https://www.ncbi.nlm.nih.gov/pubmed/30105218
http://dx.doi.org/10.2147/ITT.S125070
work_keys_str_mv AT rajushine reviewofcheckpointimmunotherapyforthemanagementofnonsmallcelllungcancer
AT josephranjit reviewofcheckpointimmunotherapyforthemanagementofnonsmallcelllungcancer
AT sehgalsameep reviewofcheckpointimmunotherapyforthemanagementofnonsmallcelllungcancer